← Back to Search

Behavioral Intervention

Cognitive Behavioral Therapy for Depression

N/A
Waitlist Available
Led By Sabine Wilhelm, PhD
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 18 or older
Be older than 18 years old
Must not have
Received more than 4 sessions of CBT for the target disorder within the past 3 years
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at baseline, and at visits 1 through 24, which will occur approximately 1 week apart.
Awards & highlights

Summary

This trial will test whether cognitive-behavioral therapy can improve clinical care outcomes at MGH.

Who is the study for?
Adults over 18 who can consent and follow study procedures, with conditions like anxiety, depression, ADHD, eating disorders, PTSD, OCD or chronic medical concerns. They must be patients or employees at MGH. Excluded if they have mental retardation, psychosis, recent CBT treatment for the same issue or are actively suicidal.Check my eligibility
What is being tested?
The trial is testing how well cognitive behavioral therapy (CBT) works when provided by unlicensed professionals to treat a variety of mental health and behavioral issues at Massachusetts General Hospital.See study design
What are the potential side effects?
CBT is generally safe but may cause temporary discomfort as individuals confront and work through difficult emotions and behaviors during therapy sessions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had over 4 CBT sessions for my condition in the last 3 years.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at baseline, and at visits 1 through 24, which will occur approximately 1 week apart.
This trial's timeline: 3 weeks for screening, Varies for treatment, and at baseline, and at visits 1 through 24, which will occur approximately 1 week apart. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The Schwartz Outcome Scale (SOS-10)

Side effects data

From 2008 Phase 3 trial • 150 Patients • NCT00074802
56%
Decreased Libido
56%
Anorgasmia
56%
Weight Gain
53%
Somnolence
47%
Fatigue
34%
Headache
34%
Nervousness
28%
Lightheadedness
28%
Nasal Congestion
28%
Insomnia
25%
Dry Mouth
22%
Weight Loss
22%
Tremor
19%
Nausea
19%
Urinary Congestion
16%
Palpitations
16%
Constipation
13%
Vomiting
13%
Sweating
13%
Tachycardia
13%
Dermatitis
13%
Diarrhea
13%
Rigidity
9%
Parathesias
9%
Photophobia
9%
Impaired Coordination
6%
Bradycardia
6%
Myalgia
6%
Blurry Vision
100%
80%
60%
40%
20%
0%
Study treatment Arm
Paroxetine With CBT Augmentation
Paroxetine Continuation

Trial Design

2Treatment groups
Experimental Treatment
Group I: Cognitive Behavioral TherapyExperimental Treatment1 Intervention
Group II: Behavioral Medicine with Cognitive Behavioral TherapyExperimental Treatment1 Intervention
Participants enrolled in this arm of this study will be treated by the behavioral medicine interns with cognitive behavioral therapy focused on both their general health concerns and mental health concerns.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cognitive behavioral therapy (CBT)
2002
Completed Phase 3
~2020

Find a Location

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor
2,955 Previous Clinical Trials
13,212,428 Total Patients Enrolled
186 Trials studying Depression
32,119 Patients Enrolled for Depression
Sabine Wilhelm, PhDPrincipal InvestigatorMassachusetts General Hospital
12 Previous Clinical Trials
671 Total Patients Enrolled
2 Trials studying Depression
112 Patients Enrolled for Depression

Media Library

Cognitive Behavioral Therapy (CBT) (Behavioral Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT01075672 — N/A
Depression Research Study Groups: Cognitive Behavioral Therapy, Behavioral Medicine with Cognitive Behavioral Therapy
Depression Clinical Trial 2023: Cognitive Behavioral Therapy (CBT) Highlights & Side Effects. Trial Name: NCT01075672 — N/A
Cognitive Behavioral Therapy (CBT) (Behavioral Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01075672 — N/A
~7 spots leftby Jan 2025